SillaJen Inc. has priced its shares at the bottom of the proposed band for a domestic initial public offering but has nevertheless drawn robust interest from retail investors who are counting on the potential of the South Korean venture’s oncolytic virus-based immunotherapy.
During the book building for the IPO, SillaJen's shares were priced at KRW15,000 ($12.84), the bottom of the proposed band...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?